Defective Regulation of Autophagy upon Leucine Deprivation Reveals a Targetable Liability of Human Melanoma Cells In Vitro and In Vivo
Name
Sheen-2011-Defective Regulation.pdf
Size
2.96 MB
Format
Adobe PDF
Checksum (MD5)
010b38f9dd9dc15d1cb8d7f80dbba10f
Author(s)
Sheen, Joon-Ho
Zoncu, Roberto
Kim, Dohoon
Sabatini, David M.
Sabatini, David
Date Issued
May 2011
Journal
Cancer Cell
Publisher
Elsevier
Citation
Sheen, Joon-Ho, Roberto Zoncu, Dohoon Kim, and David M. Sabatini. “Defective Regulation of Autophagy Upon Leucine Deprivation Reveals a Targetable Liability of Human Melanoma Cells In Vitro and In Vivo.” Cancer Cell 19, no. 5 (May 2011): 613–628. © 2011 Elsevier Inc.
Version
Final published version
Abstract
Autophagy is of increasing interest as a target for cancer therapy. We find that leucine deprivation causes the caspase-dependent apoptotic death of melanoma cells because it fails to appropriately activate autophagy. Hyperactivation of the RAS-MEK pathway, which is common in melanoma, prevents leucine deprivation from inhibiting mTORC1, the main repressor of autophagy under nutrient-rich conditions. In an in vivo tumor xenograft model, the combination of a leucine-free diet and an autophagy inhibitor synergistically suppresses the growth of human melanoma tumors and triggers widespread apoptosis of the cancer cells. Together, our study represents proof of principle that anticancer effects can be obtained with a combination of autophagy inhibition and strategies to deprive tumors of leucine.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Whitehead Institute for Biomedical Research
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.ccr.2011.03.012
